Kara L Marlatt1, Julia Steinberger2, Kyle D Rudser3, Donald R Dengel2,4, Karim T Sadak2, Jill L Lee2, Anne H Blaes5,6, Daniel A Duprez6, Joanna L Perkins5, Julie A Ross2, Aaron S Kelly2,6. 1. 1Pennington Biomedical Research Center, Baton Rouge, Louisiana. 2. 2Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota. 3. 3Division of Biostatistics, School of Public Health, and Clinical and Translational Science Institute, University of Minnesota, Minneapolis, Minnesota. 4. 4Laboratory of Integrative Human Physiology, School of Kinesiology, University of Minnesota, Minneapolis, Minnesota. 5. 5Cancer and Blood Disorders Program, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota. 6. 6Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
Abstract
Purpose: Many adult survivors of childhood cancer are at high-risk of developing cardiovascular disease. Cancer therapy may cause damage to the vascular endothelium, thereby initiating atherosclerosis. Atorvastatin has been shown to improve endothelial function independent of reducing cholesterol, as well as reduce/slow arterial stiffness and thickening, yet has never been studied in childhood cancer survivors (CCS). Methods: Twenty-seven young adult (age 26.8 ± 6.2 years) survivors of childhood acute lymphoblastic leukemia or Non-Hodgkin's lymphoma were randomly assigned (1:1) 40 mg/day of atorvastatin or placebo for 6 months. Brachial artery flow-mediated dilation (FMD), small artery reactive hyperemia index (RHI), arterial stiffness, and carotid artery elasticity/thickness were assessed. Results: Fifteen participants completed the trial. No significant treatment effect for any vascular outcomes was observed at 6 months; however, a significant decrease in peak FMD (-3.0 [95% confidence interval [CI]: -5.3, -0.7]) and a trending significant decrease in RHI (-0.3 [95% CI: -0.62, 0.01]) was observed in the placebo group, resulting in a trend toward a treatment effects (p < 0.10). No effect on arterial stiffness, carotid arterial elasticity, or thickness was observed. Conclusion: Six months of atorvastatin treatment did not improve endothelial function or arterial stiffness in young adult CCS. While a trend toward an improvement in endothelial function was present, findings should be interpreted with caution owing to the small number of evaluable participants and subsequent lack of sufficient power. Further research in a larger sample size is needed to fully elucidate the effects of atorvastatin on vascular function. Trial registered at clinicaltrials.gov as NCT01733953.
Purpose: Many adult survivors of childhood cancer are at high-risk of developing cardiovascular disease. Cancer therapy may cause damage to the vascular endothelium, thereby initiating atherosclerosis. Atorvastatin has been shown to improve endothelial function independent of reducing cholesterol, as well as reduce/slow arterial stiffness and thickening, yet has never been studied in childhood cancer survivors (CCS). Methods: Twenty-seven young adult (age 26.8 ± 6.2 years) survivors of childhood acute lymphoblastic leukemia or Non-Hodgkin's lymphoma were randomly assigned (1:1) 40 mg/day of atorvastatin or placebo for 6 months. Brachial artery flow-mediated dilation (FMD), small artery reactive hyperemia index (RHI), arterial stiffness, and carotid artery elasticity/thickness were assessed. Results: Fifteen participants completed the trial. No significant treatment effect for any vascular outcomes was observed at 6 months; however, a significant decrease in peak FMD (-3.0 [95% confidence interval [CI]: -5.3, -0.7]) and a trending significant decrease in RHI (-0.3 [95% CI: -0.62, 0.01]) was observed in the placebo group, resulting in a trend toward a treatment effects (p < 0.10). No effect on arterial stiffness, carotid arterial elasticity, or thickness was observed. Conclusion: Six months of atorvastatin treatment did not improve endothelial function or arterial stiffness in young adult CCS. While a trend toward an improvement in endothelial function was present, findings should be interpreted with caution owing to the small number of evaluable participants and subsequent lack of sufficient power. Further research in a larger sample size is needed to fully elucidate the effects of atorvastatin on vascular function. Trial registered at clinicaltrials.gov as NCT01733953.
Authors: Michel L Hijmering; Erik S G Stroes; Jobien Olijhoek; Barbara A Hutten; Peter J Blankestijn; Ton J Rabelink Journal: J Am Coll Cardiol Date: 2002-02-20 Impact factor: 24.094
Authors: Y Rikitake; S Kawashima; S Takeshita; T Yamashita; H Azumi; M Yasuhara; H Nishi; N Inoue; M Yokoyama Journal: Atherosclerosis Date: 2001-01 Impact factor: 5.162
Authors: K C Oeffinger; G R Buchanan; D A Eshelman; M A Denke; T C Andrews; J A Germak; G E Tomlinson; L E Snell; B M Foster Journal: J Pediatr Hematol Oncol Date: 2001-10 Impact factor: 1.289
Authors: D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield Journal: Lancet Date: 1992-11-07 Impact factor: 79.321
Authors: A C Mertens; Y Yasui; J P Neglia; J D Potter; M E Nesbit; K Ruccione; W A Smithson; L L Robison Journal: J Clin Oncol Date: 2001-07-01 Impact factor: 50.717
Authors: James G Gurney; Kirsten K Ness; Marilyn Stovall; Suzanne Wolden; Judy A Punyko; Joseph P Neglia; Ann C Mertens; Roger J Packer; Leslie L Robison; Charles A Sklar Journal: J Clin Endocrinol Metab Date: 2003-10 Impact factor: 6.134
Authors: Wendy J Bottinor; Debra L Friedman; Thomas D Ryan; Li Wang; Chang Yu; Scott C Borinstein; Justin Godown Journal: Cancer Med Date: 2020-06-18 Impact factor: 4.452